# Renaud Du Pasquier

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 136 papers | 7,456 citations | 71102 41 h-index | 56724 83 g-index |
| 139 all docs | 139 docs citations | 139 times ranked | 10312 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation. Immunity, 2011, 34, 213-223. | 14.3 | 810 |
| 2 | Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. Aids, 2010, 24, 1243-1250. | 2.2 | 592 |
| 3 | EFNS guidelines on diagnosis and management of neuromyelitis optica. European Journal of Neurology, 2010, 17, 1019-1032. | 3.3 | 376 |
| 4 | Elevated Tribbles homolog 2â€“specific antibody levels in narcolepsy patients. Journal of Clinical Investigation, 2010, 120, 713-719. | 8.2 | 263 |
| 5 | Functional signatures of protective antiviral Tâ€cell immunity in human virus infections. Immunological Reviews, 2006, 211, 236-254. | 6.0 | 256 |
| 6 | Chronic Parkinsonism Associated With Cirrhosis. Archives of Neurology, 2003, 60, 521. | 4.5 | 233 |
| 7 | Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257. | 10.2 | 210 |
| 8 | Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Multiple Sclerosis Journal, 2016, 22, 1550-1559. | 3.0 | 202 |
| 9 | A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain, 2004, 127, 1970-1978. | 7.6 | 188 |
| 10 | Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain, 2008, 131, 1712-1721. | 7.6 | 150 |
| 11 | Two patients with acute meningoencephalitis concomitant with SARSâ€CoVâ€2 infection. European Journal of Neurology, 2020, 27, e43-e44. | 3.3 | 149 |
| 12 | Inflammatory Reaction in Progressive Multifocal Leukoencephalopathy: Harmful or Beneficial?. Journal of NeuroVirology, 2003, 9, 25-31. | 2.1 | 135 |
| 13 | Association of Prolonged Survival in HLA-A2+ Progressive Multifocal Leukoencephalopathy Patients with a CTL Response Specific for a Commonly Recognized JC Virus Epitope. Journal of Immunology, 2002, 168, 499-504. | 0.8 | 129 |
| 14 | Interplay of Cellular and Humoral Immune Responses against BK Virus in Kidney Transplant Recipients with Polyomavirus Nephropathy. Journal of Virology, 2006, 80, 3495-3505. | 3.4 | 129 |
| 15 | JC Virus-Specific Cytotoxic T Lymphocytes in Individuals with Progressive Multifocal Leukoencephalopathy. Journal of Virology, 2001, 75, 3483-3487. | 3.4 | 125 |
| 16 | The effect of aging on postural stability: a cross sectional and longitudinal study. Neurophysiologie Clinique, 2003, 33, 213-218. | 2.2 | 116 |
| 17 | Human Induced Pluripotent Stem Cell-Derived Astrocytes Are Differentially Activated by Multiple Sclerosis-Associated Cytokines. Stem Cell Reports, 2018, 11, 1199-1210. | 4.8 | 114 |
| 18 | Pattern of cognitive deficits in severe COVID-19. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 567-568. | 1.9 | 108 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Fatal PML associated with efalizumab therapy. Neurology, 2012, 78, 458-467. | 1.1 | 103 |
| 20 | The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes. Cell Reports, 2017, 20, 2980-2991. | 6.4 | 96 |
| 21 | Magnetic resonance imaging and proton spectroscopic alterations correlate with parkinsonian signs in patients with cirrhosis. Gastroenterology, 2000, 119, 774-781. | 1.3 | 94 |
| 22 | Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. Annals of Neurology, 2020, 88, 1034-1042. | 5.3 | 89 |
| 23 | Natalizumab may control immune checkpoint inhibitorâ€“induced limbic encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e439. | 6.0 | 87 |
| 24 | Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurology, The, 2010, 9, 264-272. | 10.2 | 86 |
| 25 | Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes. Journal of Neuroinflammation, 2015, 12, 119. | 7.2 | 85 |
| 26 | Low Frequency of Cytotoxic T Lymphocytes against the Novel HLA-A*0201-Restricted JC Virus Epitope VP1 p36 in Patients with Proven or Possible Progressive Multifocal Leukoencephalopathy. Journal of Virology, 2003, 77, 11918-11926. | 3.4 | 84 |
| 27 | Intrathecal immune responses to EBV in early MS. European Journal of Immunology, 2010, 40, 878-887. | 2.9 | 83 |
| 28 | Impairment of JCV-specific T-cell response by corticotherapy. Neurology, 2012, 79, 2258-2264. | 1.1 | 82 |
| 29 | Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects. Journal of Neuroimmunology, 2011, 233, 240-244. | 2.3 | 80 |
| 30 | Detection of JC Virus-Specific Cytotoxic T Lymphocytes in Healthy Individuals. Journal of Virology, 2004, 78, 10206-10210. | 3.4 | 78 |
| 31 | Severe but reversible encephalopathy associated with cefepime. Neurophysiologie Clinique, 2000, 30, 383-386. | 2.2 | 77 |
| 32 | JC Virus-Specific Immune Responses in Human Immunodeficiency Virus Type 1 Patients with Progressive Multifocal Leukoencephalopathy. Journal of Virology, 2009, 83, 4404-4411. | 3.4 | 74 |
| 33 | Advanced MRI unravels the nature of tissue alterations in early multiple sclerosis. Annals of Clinical and Translational Neurology, 2014, 1, 423-432. | 3.7 | 67 |
| 34 | Status epilepticus of inflammatory etiology. Neurology, 2015, 85, 464-470. | 1.1 | 64 |
| 35 | Automated detection of white matter and cortical lesions in early stages of multiple sclerosis. Journal of Magnetic Resonance Imaging, 2016, 43, 1445-1454. | 3.4 | 64 |
| 36 | Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1079-1082. | 1.9 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | PML risk stratification using anti-JCV antibody index and L-selectin. Multiple Sclerosis Journal, 2016, 22, 1048-1060. | 3.0 | 62 |
| 38 | CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis. Clinical Immunology, 2007, 123, 105-113. | 3.2 | 57 |
| 39 | Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. Neurology, 2021, 97, e543-e553. | 1.1 | 54 |
| 40 | A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Multiple Sclerosis Journal, 2015, 21, 885-893. | 3.0 | 53 |
| 41 | Advancing human induced pluripotent stem cellâ€derived bloodâ€brain barrier models for studying immune cell interactions. FASEB Journal, 2020, 34, 16693-16715. | 0.5 | 47 |
| 42 | The â€œcentral vein signâ€•in patients with diagnostic â€œred flagsâ€•for multiple sclerosis: A prospective multicenter 3T study. Multiple Sclerosis Journal, 2020, 26, 421-432. | 3.0 | 44 |
| 43 | A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients â€" A twelve month follow-up. Journal of Neuroimmunology, 2015, 285, 68-70. | 2.3 | 41 |
| 44 | Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurology, 2022, 79, 682. | 9.0 | 41 |
| 45 | Immunological and clinical consequences of treating a patient with natalizumab. Multiple Sclerosis Journal, 2012, 18, 335-344. | 3.0 | 40 |
| 46 | Motor behavior unmasks residual cognition in disorders of consciousness. Annals of Neurology, 2019, 85, 443-447. | 5.3 | 40 |
| 47 | EBI2 Expression and Function: Robust in Memory Lymphocytes and Increased by Natalizumab in Multiple Sclerosis. Cell Reports, 2017, 18, 213-224. | 6.4 | 38 |
| 48 | The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS ONE, 2016, 11, e0152347. | 2.5 | 38 |
| 49 | Intrinsic bloodâ€“brain barrier dysfunction contributes to multiple sclerosis pathogenesis. Brain, 2022, 145, 4334-4348. | 7.6 | 37 |
| 50 | Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. Aids, 2005, 19, 2069-2076. | 2.2 | 36 |
| 51 | HLA-B7â€“Restricted EBV-Specific CD8+ T Cells Are Dysregulated in Multiple Sclerosis. Journal of Immunology, 2012, 188, 4671-4680. | 0.8 | 36 |
| 52 | Increased ex vivo antigen presentation profile of B cells in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 802-809. | 3.0 | 36 |
| 53 | CSF lactate for accurate diagnosis of community-acquired bacterial meningitis. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2049-2055. | 2.9 | 35 |
| 54 | The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment. Open Forum Infectious Diseases, 2017, 4, ofx070. | 0.9 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, . | 6.0 | 34 |
| 56 | Neuromyelitis optica following CMV primo-infection. Journal of Internal Medicine, 2007, 261, 500-503. | 6.0 | 32 |
| 57 | Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. Cellular and Molecular Life Sciences, 2012, 69, 3395-3418. | 5.4 | 32 |
| 58 | Rivastigmine for HIV-associated neurocognitive disorders. Neurology, 2013, 80, 553-560. | 1.1 | 32 |
| 59 | Exploring the effect of vitamin D<sub>3</sub> supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1280-1287. | 3.0 | 32 |
| 60 | CVSnet: A machine learning approach for automated central vein sign assessment in multiple sclerosis. NMR in Biomedicine, 2020, 33, e4283. | 2.8 | 31 |
| 61 | Multicontrast connectometry: A new tool to assess cerebellum alterations in early relapsingâ€remitting multiple sclerosis. Human Brain Mapping, 2015, 36, 1609-1619. | 3.6 | 30 |
| 62 | JC virus induces a vigorous CD8+ cytotoxic T cell response in multiple sclerosis patients. Journal of Neuroimmunology, 2006, 176, 181-186. | 2.3 | 27 |
| 63 | The Combined Quantification and Interpretation of Multiple Quantitative Magnetic Resonance Imaging Metrics Enlightens Longitudinal Changes Compatible with Brain Repair in Relapsing-Remitting Multiple Sclerosis Patients. Frontiers in Neurology, 2017, 8, 506. | 2.4 | 27 |
| 64 | Periodic downbeat nystagmus. Neurology, 1998, 51, 1478-1480. | 1.1 | 26 |
| 65 | Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis. CNS Drugs, 2014, 28, 535-558. | 5.9 | 26 |
| 66 | Progressive decline of decision-making performances during multiple sclerosis. Journal of the International Neuropsychological Society, 2009, 15, 291-295. | 1.8 | 25 |
| 67 | Demyelination as a complication of new immunomodulatory treatments. Current Opinion in Neurology, 2010, 23, 226-233. | 3.6 | 25 |
| 68 | MP2RAGE provides new clinically-compatible correlates of mild cognitive deficits in relapsing-remitting multiple sclerosis. Journal of Neurology, 2014, 261, 1606-1613. | 3.6 | 24 |
| 69 | Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e401. | 6.0 | 24 |
| 70 | Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. Aids, 2013, 27, 203-210. | 2.2 | 23 |
| 71 | Multiple Sclerosis Decreases Explicit Counterfactual Processing and Risk Taking in Decision Making. PLoS ONE, 2012, 7, e50718. | 2.5 | 23 |
| 72 | Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine. Journal of NeuroVirology, 2015, 21, 694-701. | 2.1 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | RimNet: A deep 3D multimodal MRI architecture for paramagnetic rim lesion assessment in multiple sclerosis. NeuroImage: Clinical, 2020, 28, 102412. | 2.7 | 21 |
| 74 | Environmental factors in multiple sclerosis. Presse Medicale, 2015, 44, e113-e120. | 1.9 | 20 |
| 75 | Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland. Open Forum Infectious Diseases, 2019, 6, ofz277. | 0.9 | 20 |
| 76 | Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High Field. PLoS ONE, 2013, 8, e72547. | 2.5 | 19 |
| 77 | Advances in Treatment of Progressive Multifocal Leukoencephalopathy. Annals of Neurology, 2021, 90, 865-873. | 5.3 | 18 |
| 78 | Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis. Neurology, 2011, 76, 757-758. | 1.1 | 16 |
| 79 | Multicontrast MRI Quantification of Focal Inflammation and Degeneration in Multiple Sclerosis. BioMed Research International, 2015, 2015, 1-9. | 1.9 | 16 |
| 80 | Natalizumab treatment alters the expression of T-cell trafficking marker LFA-1 Î±-chain (CD11a) in MS patients. Multiple Sclerosis Journal, 2014, 20, 837-842. | 3.0 | 15 |
| 81 | Chimeric immune receptors (CIRs) specific to JC virus for immunotherapy in progressive multifocal leukoencephalopathy (PML). International Immunology, 2007, 19, 1083-1093. | 4.0 | 14 |
| 82 | HIV Testing Practices by Clinical Service before and after Revised Testing Guidelines in a Swiss University Hospital. PLoS ONE, 2012, 7, e39299. | 2.5 | 14 |
| 83 | Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes. Neurology, 2016, 86, 1780-1784. | 1.1 | 14 |
| 84 | Persistence of mild parkinsonism 4 months after liver transplantation in patients with preoperative minimal hepatic encephalopathy: a study on neuroradiological and blood manganese changes. Transplant International, 2002, 15, 188-195. | 1.6 | 12 |
| 85 | Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment. Multiple Sclerosis and Related Disorders, 2021, 51, 102918. | 2.0 | 11 |
| 86 | Differentiation of functional astrocytes from human-induced pluripotent stem cells in chemically defined media. STAR Protocols, 2021, 2, 100902. | 1.2 | 11 |
| 87 | Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. Clinical Mass Spectrometry, 2018, 8, 8-20. | 1.9 | 10 |
| 88 | Anaphylactic reaction to methylprednisolone in multiple sclerosis: a practical approach to alternative corticosteroids. Multiple Sclerosis Journal, 2007, 13, 559-560. | 3.0 | 9 |
| 89 | Monocular Central Dazzle After Thalamic Infarcts. Journal of Neuro-Ophthalmology, 2000, 20, 97-99. | 0.8 | 8 |
| 90 | Assessing risks of multiple sclerosis therapies. Journal of the Neurological Sciences, 2013, 332, 59-65. | 0.6 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Relapse in herpes simplex virus encephalitis. Neurology, 2015, 85, 1730-1731. | 1.1 | 8 |
| 92 | Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes. Frontiers in Neurology, 2020, 11, 973. | 2.4 | 8 |
| 93 | Vaccine-associated measles in a patient treated with natalizumab: a case report. BMC Infectious Diseases, 2020, 20, 753. | 2.9 | 8 |
| 94 | Severe post-EBV encephalopathy associated with myelin oligodendrocyte glycoprotein-specific immune response. Journal of Neuroimmunology, 2007, 192, 192-197. | 2.3 | 7 |
| 95 | A New Approach for Deep Gray Matter Analysis Using Partial-Volume Estimation. PLoS ONE, 2016, 11, e0148631. | 2.5 | 7 |
| 96 | Neurodegenerative phagocytes mediate synaptic stripping in Neuro-HIV. Brain, 2022, 145, 2730-2741. | 7.6 | 7 |
| 97 | Minimal supportive treatment in natalizumab-related PML in a MS patient. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 354-355. | 1.9 | 6 |
| 98 | Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence. Multiple Sclerosis Journal, 2017, 23, 300-303. | 3.0 | 6 |
| 99 | Efficacy of Natalizumab in Intermediate Uveitis Related to Multiple Sclerosis: A Case Report. Klinische Monatsblatter Fur Augenheilkunde, 2018, 235, 476-477. | 0.5 | 6 |
| 100 | Late Lyme neuroborreliosis with chronic encephalomyelitis. Neurology, 2018, 91, 627-628. | 1.1 | 6 |
| 101 | Reader response: Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology, 2019, 92, 151-151. | 1.1 | 6 |
| 102 | Neurocognitive course at two-year follow-up in the neurocognitive assessment in the metabolic and aging cohort (NAMACO) study. Aids, 2021, Publish Ahead of Print, 2469-2480. | 2.2 | 6 |
| 103 | Discrepant findings in immune responses to JC virus in patients receiving natalizumab â€“ Authors' reply. Lancet Neurology, The, 2010, 9, 566-567. | 10.2 | 5 |
| 104 | Acute Lyme Neuroborreliosis With Transient Hemiparesis and Aphasia. Annals of Emergency Medicine, 2015, 66, 60-64. | 0.6 | 5 |
| 105 | The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e209. | 6.0 | 5 |
| 106 | Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary. Clinical and Translational Neuroscience, 2019, 3, 2514183X1882207. | 0.9 | 5 |
| 107 | Vaccination in B-cellâ€“depleted patients with multiple sclerosis. Neurology, 2020, 95, 613-614. | 1.1 | 5 |
| 108 | The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland. International Journal of STD and AIDS, 2021, 32, 729-739. | 1.1 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Case Report: Behavioral Unresponsiveness in Acute COVID-19 Patients: The Utility of the Motor Behavior Tool-Revised and 18F-FDG PET/CT. Frontiers in Neurology, 2021, 12, 644848. | 2.4 | 5 |
| 110 | Cytokine mRNA profile of Epsteinâ€“Barr virus-stimulated highly differentiated T cells in multiple sclerosis: A pilot study. Journal of Neuroimmunology, 2010, 225, 167-170. | 2.3 | 4 |
| 111 | MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects. Neurological Sciences, 2013, 34, 539-543. | 1.9 | 4 |
| 112 | Immune system's role in viral encephalitis. Revue Neurologique, 2014, 170, 577-583. | 1.5 | 4 |
| 113 | Human Leukocyte Antigen Genotype as a Marker of Multiple Sclerosis Prognosis. Canadian Journal of Neurological Sciences, 2020, 47, 189-196. | 0.5 | 4 |
| 114 | Unexpected worsening of progressive multifocal leucoencephalopathy following COVID-19 pneumonia. Journal of NeuroVirology, 2021, 27, 510-513. | 2.1 | 4 |
| 115 | Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013â€“2017, in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2020, 71, 637-644. | 5.8 | 3 |
| 116 | Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland. PLoS ONE, 2021, 16, e0246579. | 2.5 | 3 |
| 117 | Limbic Encephalitis: Another Example of Molecular Mimicry?. European Neurology, 2007, 57, 191-192. | 1.4 | 2 |
| 118 | Inaugural description of Cogan syndrome in an HIV-infected person. Journal of Neurology, 2008, 255, 1427-1428. | 3.6 | 2 |
| 119 | A light in the cognitive fog?. Antiviral Therapy, 2013, 18, 149-151. | 1.0 | 2 |
| 120 | Management of Fulminant Multiple Sclerosis With Rituximab. Neurologist, 2015, 19, 155-157. | 0.7 | 2 |
| 121 | An unusual case of miliary PML-IRIS in an HIV+ patient. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e370. | 6.0 | 2 |
| 122 | Is disease activity prior to fingolimod initiation predictive of response? Fingolimod as a â€œcommonâ€• first line treatment. Revue Neurologique, 2021, 177, 935-940. | 1.5 | 2 |
| 123 | Anti-Adenylate Kinase 5 Encephalitis With Histologic Evidence of CNS Vasculitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1010. | 6.0 | 2 |
| 124 | Encephalitis with herpes simplex-2 in the cerebrospinal fluid and anti-RI (ANNA-2) antibodies: an infectious or a paraneoplastic syndrome?. BMJ Case Reports, 2009, 2009, bcr1220081363-bcr1220081363. | 0.5 | 2 |
| 125 | Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk. Annals of Neurology, 2016, 80, 791-791. | 5.3 | 1 |
| 126 | Rivastigmine decreases brain damage in <scp>HIV</scp> patients with mild cognitive deficits. Annals of Clinical and Translational Neurology, 2017, 4, 915-920. | 3.7 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Meningeal Relapse of Nodular Lymphocyte Predominant Hodgkin Lymphoma Transformed to T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Case Report. Frontiers in Oncology, 2020, 10, 1745. | 2.8 | 1 |
| 128 | Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm. Leukemia and Lymphoma, 2020, 61, 2226-2229. | 1.3 | 1 |
| 129 | Authorsâ€™ reply to A. Winston, A. Cotter, M. Gisslen, P. W. G. Mallon and P. Cinque. HIV Medicine, 2020, 21, e19-e20. | 2.2 | 1 |
| 130 | A promenade along the stream of demyelination. Current Opinion in Neurology, 2010, 23, 203-204. | 3.6 | 0 |
| 131 | 327. Genetic Editing for Huntington's Disease. Molecular Therapy, 2016, 24, S131. | 8.2 | 0 |
| 132 | A Swiss neurological paradox. Clinical and Translational Neuroscience, 2018, 2, 2514183X1878525. | 0.9 | 0 |
| 133 | Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015. BMJ Open, 2018, 8, e021203. | 1.9 | 0 |
| 134 | Clinical Reasoning: A 69-year-old man with rare complex visual symptoms. Neurology, 2020, 95, 316-320. | 1.1 | 0 |
| 135 | First-ever treatment in multiple sclerosis. Revue Neurologique, 2021, 177, 93-99. | 1.5 | 0 |
| 136 | Discussing Challenges in Diagnosis of Tuberculous Meningitis and Neurosarcoidosis. Canadian Journal of Neurological Sciences, 2021, , 1-7. | 0.5 | 0 |